Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Flexible iris claw phakic intraocular lens (Artiflex®) implantation for high myopia

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Phakic IOLs I

Session Date/Time: Monday 07/09/2015 | 14:30-16:30

Paper Time: 14:48

Venue: Room 10

First Author: : J.Pires PORTUGAL

Co Author(s): :    T. Queiros   T. Monteiro   N. Franqueira   F. Faria-Correia   F. Vaz        

Abstract Details

Purpose:

To evaluate the efficacy and safety of the Artiflex® (Ophtec BV, Groningen, Netherlands) phakic intraocular lens (PIOL) implantation for correction of high myopia.

Setting:

Ophthalmology department of Hospital de Braga, Portugal.

Methods:

We reviewed 170 myopic eyes of 94 patients undergoing Artiflex® PIOL implantation for high myopia correction, between January 2012 and June 2014. Post-operative follow-up was of 6 - 36 months. Preoperative and follow-up data were analyzed regarding to best-corrected visual acuity (BCVA), spherical and cylindrical refractions, keratometry, corneal endothelial cells count (CECC) and anterior chamber depth (ACD). The Efficacy and Safety Indexes of the procedure were also calculated. Corneal topography was performed using Oculus Pentacam (OCULUS Optikgerate GmbH®, Wetzlar, Germany).

Results:

There was a significant improvement in BCVA from 0,78 preoperatively to 0,91 postoperatively. The spherical equivalent improved from -9,71 D ± 3,82 to -0,30 D ± 0,40 at 12 months follow up and to -0,33 D ± 0,53 at 24 months follow-up; after 36 months we observed a slight regression to -1,15 D ± 0,41. The Efficacy Index was 0,98 and the Safety Index was 1,16. Vectorial analysis for keratometric astigmatism showed a mean surgically induced astigmatism of 0,25 D. We found a mean cell loss of 3,0% per year at 36 months. The ACD measurements showed a decrease of 6,96% from a mean preoperative value of 3,16 mm ± 0,23 to 2,94 mm ± 0,24 at 36 months.

Conclusions:

The Artiflex® PIOL is an effective and safe option for high myopia treatment. A careful annual follow-up is mandatory to monitor the endothelial cell count and eventual changes of the anterior chamber morphology.

Financial Interest:

NONE

Back to previous